Animal toxicity findings with ARO-ENaC come not long after Ionis’s similar setback.
NOV03 posts a pivotal win but the late-stage dry eye pipeline is crowded.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Pharmamar’s pivotal small cell lung cancer trial is finally confirmed a dud, but will the FDA pull Zepzelca from the market?
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
US drug stocks were shielded from bigger falls in the first quarter by leading coronavirus researchers, leaving groups listed in Japan and Europe to tumble harder.
Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.